IGC Pharma Earnings Call Transcripts
Fiscal Year 2026
-
Phase II CALMA trial for a cannabinoid-based Alzheimer's therapy is 70% enrolled and on track for completion by mid-year, with top-line data expected by late summer. The MINT-AD AI platform for Alzheimer's risk assessment will enter beta testing soon, and regulatory trends favor expansion of cannabinoid-based treatments.
Fiscal Year 2025
-
IGC 81's phase two trial for Alzheimer's agitation surpassed 50% enrollment, with accelerated recruitment and expansion to 35 sites in the U.S. and Canada. Strategic divestment improved financials, and the AI-based MINT-AD platform advanced to the semifinals for a $1M research prize.
-
IGC81 demonstrated rapid and significant efficacy in phase II trials for Alzheimer's agitation, while the AI-based MINT-AD platform advanced early detection capabilities. Efficient capital management and pipeline expansion into GLP-1 agonists position the company for growth.